CONMED Net Worth
CONMED Net Worth Breakdown | CNMD |
CONMED Net Worth Analysis
CONMED's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including CONMED's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of CONMED's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform CONMED's net worth analysis. One common approach is to calculate CONMED's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares CONMED's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing CONMED's net worth. This approach calculates the present value of CONMED's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of CONMED's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate CONMED's net worth. This involves comparing CONMED's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into CONMED's net worth relative to its peers.
Enterprise Value |
|
To determine if CONMED is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CONMED's net worth research are outlined below:
| CONMED generated a negative expected return over the last 90 days | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Additional Considerations Required While Assessing CONMEDs Strong Earnings |
CONMED Quarterly Good Will |
|
CONMED uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CONMED. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CONMED's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know CONMED's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CONMED is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CONMED backward and forwards among themselves. CONMED's institutional investor refers to the entity that pools money to purchase CONMED's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fuller & Thaler Asset Management Inc | 2024-12-31 | 862.7 K | Jpmorgan Chase & Co | 2024-09-30 | 849.5 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 775.4 K | Geode Capital Management, Llc | 2024-12-31 | 692.8 K | Cooke & Bieler Lp | 2024-12-31 | 664 K | Principal Financial Group Inc | 2024-12-31 | 625.1 K | Deerfield Management Co | 2024-12-31 | 612 K | Clearbridge Advisors, Llc | 2024-12-31 | 543 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 494.9 K | Blackrock Inc | 2024-12-31 | 4.9 M | Vanguard Group Inc | 2024-12-31 | 3.6 M |
Follow CONMED's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.94 B.Market Cap |
|
Project CONMED's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.15 | 0.08 | |
| Return On Capital Employed | 0.10 | 0.09 | |
| Return On Assets | 0.06 | 0.04 | |
| Return On Equity | 0.14 | 0.07 |
When accessing CONMED's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures CONMED's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CONMED's profitability and make more informed investment decisions.
Please note, the presentation of CONMED's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CONMED's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CONMED's management manipulating its earnings.
Evaluate CONMED's management efficiency
CONMED has return on total asset (ROA) of 0.0432 % which means that it generated a profit of $0.0432 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1474 %, meaning that it created $0.1474 on every $100 dollars invested by stockholders. CONMED's management efficiency ratios could be used to measure how well CONMED manages its routine affairs as well as how well it operates its assets and liabilities. As of February 25, 2025, Return On Tangible Assets is expected to decline to 0.08. In addition to that, Return On Capital Employed is expected to decline to 0.09. At present, CONMED's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 122.2 M, whereas Net Tangible Assets are projected to grow to (642.7 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 31.21 | 32.77 | |
| Tangible Book Value Per Share | (14.92) | (14.18) | |
| Enterprise Value Over EBITDA | 10.99 | 18.68 | |
| Price Book Value Ratio | 2.19 | 1.28 | |
| Enterprise Value Multiple | 10.99 | 18.68 | |
| Price Fair Value | 2.19 | 1.28 | |
| Enterprise Value | 780.6 M | 819.6 M |
CONMED has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 2.1398 | Revenue | Quarterly Revenue Growth 0.058 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CONMED insiders, such as employees or executives, is commonly permitted as long as it does not rely on CONMED's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CONMED insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CONMED Corporate Filings
8K | 25th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 18th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F4 | 13th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 31st of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
CONMED Earnings per Share Projection vs Actual
CONMED Corporate Directors
| John Workman | Independent Director | Profile | |
| Charles Farkas | Independent Director | Profile | |
| Jerome Lande | Independent Director | Profile | |
| David Bronson | Independent Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CONMED. If investors know CONMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CONMED listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.028 | Dividend Share 0.8 | Earnings Share 4.25 | Revenue Per Share | Quarterly Revenue Growth 0.058 |
The market value of CONMED is measured differently than its book value, which is the value of CONMED that is recorded on the company's balance sheet. Investors also form their own opinion of CONMED's value that differs from its market value or its book value, called intrinsic value, which is CONMED's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CONMED's market value can be influenced by many factors that don't directly affect CONMED's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CONMED's value and its price as these two are different measures arrived at by different means. Investors typically determine if CONMED is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CONMED's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.